Abstract: Pulmonary infections in immunocompromised patients remain a significant contributor to mortality, morbidity, and health care-associated costs in such a vulnerable patient population. Their epidemiology is changing, set forth by new trends in immunosuppressive regimens and also prophylaxis. The host characteristics, presenting clinical symptomatology, along with radiographic patterns, have also evolved. The microbiology diagnostics are now enriched with nonculture methods for better identification of the causative pathogens. Chest imaging remains the cornerstone of the initial workup. Our article will examine the new trends in epidemiology, clinical findings, and diagnostics for immunocompromised patients with pulmonary infections (transplant recipients, neutropenic hosts, HIV-infected patients, and patients with autoimmune conditions). We will also review the differential diagnosis that most of the times includes malignancies and drug or radiation-related toxicities.
T he immune system is specialized in preventing, containing, and eradicating invasive microorganisms and internal threats (eg, neoplasia). It is composed of an intricate network of proteins, cells, and organs, and failure at any level can result in increased susceptibility to infections. The immune system is commonly divided into the innate and the adaptive components. 1 The innate immune system is very well preserved and highly effective. Because it does not need to be "trained," it is the first line of defense against most pathogens. Its components can be illustrated using the respiratory system and include the following: barrier/mechanical components (eg, laryngeal reflexes, the mucocilliary escalator, and mucosal tight junctions); molecular components that recognize highly preserved microbial products such as toll-like receptors, the complement, antimicrobial peptides; the cells of the phagocytic system, including neutrophils and macrophages, basophils, NK-cells, eosinophils, and others, which can in turn secrete cytokines that help promote the adaptive immune response. 1, 2 The adaptive system is characterized by plasticity, specificity, and memory. It has humoral and cellular components comprised of the B and T lymphocytes. It recognizes antigens via T-cell receptors or antibodies produced by the B cells. When presented in the right environment, along with costimulatory molecules, they can trigger an adaptive immune response. 3 During their maturation, lymphocytes that recognize self-antigens undergo apoptosis, and lymphocytes that recognize foreign antigens, including microorganisms, are preserved.
Failure at each level can result in infectious complications. These states of increased susceptibility to infections are known as immune deficiencies, which can be primary, if present at birth, or secondary if they appear later in life, for example, after chemotherapy. 4 Given the complexity of the innate and adaptive immune response, a comprehensive review of all potential immune derangements is beyond the scope of this review. In what follows, we will focus on the opportunistic infections in the lung, including their radiographic and clinical presentation, as well as differential diagnosis.
We will review specific aspects of the following groups of patients: patients with solid and hematological malignancies including hematopoietic stem cell transplantation (HSCT) recipients, patients who have undergone solid organ transplants (SOT), and patients with human immunodeficiency virus (HIV) infection and autoimmune conditions requiring immunosuppresing medications.
COMMON FEATURES OF PULMONARY INFECTIONS IN SECONDARILY IMMUNOCOMPROMISED PATIENTS
As a general rule, one must consider the following aspects that will shape the clinical presentation and guide the clinician toward a diagnosis: the underlying disease (eg, acute myelogenous leukemia or pretransplant diagnosis of cystic fibrosis), previous therapies (eg, the type and dose of chemotherapy will determine the duration of leukopenia), risk factors for certain infections, such as geographical location (eg, travel to areas where endemic fungal infections are prevalent), and seasonality (eg, during the winter months when influenza infections are increased). In organ transplantation, the cause of death of the donor as well as presence of infectious complications in organ recipients from the same donor are part of the evaluation process. All this information must be considered against the possibility of pulmonary toxicities of chemotherapeutic drugs, pulmonary complications as a consequence of the underlying disease, and also mechanical complications (eg, pulmonary vein stenosis, as in the case of lung transplantation). [5] [6] [7] 
PRESENTATION AND DIAGNOSTIC TESTS
The typical signs and symptoms of infection will frequently be absent in immunosuppressed (IS) patients. 8 Dyspnea, hypoxemia, cough, wheezing, hemoptysis, and fever can all be present at diagnosis, but their role differentiating one type of infection from another has not been thoroughly studied. Chest pain when present suggests pleural involvement by complicated pleural effusions or extrapulmonary tissue invasion by infectious pathogens such as invasive mold infections (IMI). When present they usually signal advanced disease and poor prognosis. 8, 9 Symptoms of upper respiratory tract infection can precede both viral and bacterial pneumonias. Many infections in this group of patients can be disseminated upon presentation and list nonspecific complaints such as weight loss, fever, and fatigue.
Because the symptoms are nonspecific and frequently absent, a sizeable number of patients will present with abnormalities in screening radiologic studies or during surveillance bronchoscopies, as in the case of lung transplant recipients. This surveillance is transplant-specific and occurs in the posttransplantation period. Conversely, early imaging with computed tomography (CT) in symptomatic patients, even in the absence of chest radiograph abnormalities, often proves helpful. 10 Although in order to decrease mortality 11 empirical treatment targeting the most likely infections should be started immediately, most clinicians agree that the toxicities associated with the treatment of common pulmonary pathogens (eg, amphotericin, ganciclovir, trimethoprin-sulfamethoxazole) and the high mortality associated with misdiagnosis warrants pursuing a specific microbiological diagnosis. Although tissue samples are ideal, these are invasive and at times cannot be performed due to the prohibitive coagulopathies that frequently accompany neutropenia. Treatment is then based on the clinical presentation and associated noninvasive testing.
Among noninvasive tests used in IS patients, the galactomannan antigen has gained a lot of merit as a biomarker of invasive aspergillosis. It can be measured in plasma and bronchoalveolar lavage (BAL) fluid via commercially available sandwich enzyme-linked immunosorbent assays. A result of an optical density index of > 0.5 ng/mL in plasma or BAL is considered a positive result. The average sensitivity of 82% (73% to 90%) can be increased to 93% if the test cutoff is raised at the cost of lowering specificity levels from 81% (72% to 90%) to 61%. 12 Galactomanan performs better in patients with an absolute neutrophil count (ANC) <100 cells/mm 3 . As the ANC increases above this level, a negative test in plasma does not rule out infection. 13 False positives have been reported in patients receiving Piperacillin and Amoxicillin. BAL measurements outperform plasma in non-neutropenic patients. 14 1-3 beta-D-glucan is another cell wall component of most fungi, and, for this reason, it does not provide a specific diagnosis. It is negative in infections secondary to Cryptococcus and the Mucorales spp. False positives are reported in patients receiving blood products, including albumin and immunoglobulins, and in patients on dialysis. When used in a syndrome-driven approach, the sensitivity and specificity are 64% and 84%, respectively, 15 when a plasma level ≥ 80 pg/mL is used as the diagnostic threshold. The reproducibility of the test in BAL has been questioned by some authors. 16 Other diagnostic tests exist for mold and fungal infections, and these include polymerase chain reaction (PCR) and monoclonal antibodies. They can both be engineered to detect one or multiple mold species. Monoclonal antibodies are available as bedside rapid diagnostic tests. 17 Their role in different groups of patients (eg, neutropenic vs. non-neutropenic) is not well established, and they are not part of the European Organization for Research and Treatment of Cancer (EORTC) criteria for the diagnosis of IMI in neutropenic patients. 18 The biomarker procalcitonin is widely used in the diagnosis of community-acquired pneumonia. In healthy noninfected individuals, it is only found in thyroid C cells where it is cleaved into calcitonin and participates in calcium homeostasis. Extra thyroidal production and release into plasma occurs in inflammatory states as a result of stimulation by endotoxin and interleukins 1 and 6 among others. Interferon-gamma produced during viral infections inhibits its production. Therefore, an elevated plasma level suggests that a pneumonia is of bacterial rather than viral etiology. Its use in patients suspected of having hospitalacquired pneumonia or ventilator-associated pneumonia is, however, discouraged by the most recent IDSA guidelines, 19 limiting its usefulness in the early posttransplant period. In SOT recipients in a chronic stable state, it was found to be useful at differentiating bacterial infections from transplant rejection. 20 Procalcitonin has a delayed peak in bacterial and fungal infections in neutropenic fever, usually after 2 days in bacterial and beyond 3 days in fungal infections; thus, it is not useful at the onset of fever. 21 Free circulating DNA is released into the plasma of healthy and diseased individuals. Elevated levels of donorderived DNA in SOT and of recipient DNA in HSCT can help diagnose rejection and graft versus host disease (GVHD) without invasive diagnostic testing. 22 Since 2005, a commercial kit has been available for the diagnosis of rejection in heart transplant recipients. 22 Its major drawback at the present time is its inability to differentiate transplant rejection from infection.
In the next pages, we will review the most common pulmonary infections in IS patients.
NEUTROPENIA
Neutrophils are part of the innate immune system and are a subset of the white blood cells, accounting for 40% to 70% of total white blood cells. ANC below 1500 cells/μL are termed neutropenia, and the susceptibility to infections rises continuously, with the highest risk in patients with an ANC <500 cells/μL (severe neutropenia). Nevertheless, most infectious complications develop at an ANC <100 cells/μL. Although neutropenia can be seen as a result of multiple processes (eg, ethnic, congenital, infectious, autoimmune), we will focus on neutropenia in recipients of HSCT, in patients after chemotherapy for solid organ cancers, and in SOT recipients.
Neutropenia in Hematologic Malignancies and HSCT Recipients
Of all neutropenic patients, the group at the highest risk of infections is represented by patients with hematologic malignancies and HSCT recipients. Currently, over 19,000 and 50,000 HSCT procedures are performed annually in the United States and around the world (respectively) to treat conditions that range from congenital disorders to cancer. 23 Multiple myeloma, non-Hodgkin lymphomas, and acute myelogenous leukemia are the most common indications accounting 70% of all HSCTs. 23 During a HSCT procedure, hematopoietic stem cells (HSC) are harvested from the patient (autologous) or from another person (allogeneic from a related or unrelated donor) either from peripheral blood, the bone marrow, or the umbilical cord blood. Balancing the risk of developing GVHD-a condition where the donor immune system rejects the body of the recipientversus preserving the ability of the donor HSC to recognize tumor neo-antigens working as immunotherapy, HSCs are manipulated to include higher or lower proportions of T-cell precursors. 24 HSCs can differentiate into all mature blood cell lineages and are infused after a recipient has received a conditioning regimen that includes more or less potent chemotherapy +/− total body irradiation depending on the underlying disorder. The goals of conditioning regimens are to treat the underlying disease, produce a general state of immune suppression to aid graft implantation, and provide physical space in the marrow for the donor HSC. The last decade has seen an evolution in conditioning regimens that has resulted in less toxicities and the ability to transplant older patients with more comorbidities. 25 Finally, in the post-HSCT period, patients may require central lines, parenteral nutrition, frequent blood transfusions, and more or less intense immune suppression and infection prophylaxis.
All these factors, recipient, underlying disease, conditioning regimen, source of transplant and manipulation, and posttransplant therapies and complications, along with the local epidemiology of the center providing care, generate a complex picture that shape the risk for infectious pulmonary complications in HSCT recipients 26 (Fig. 1) .
Risk of infection is highest once the ANC has dropped to <500 cells/μL and increases with the duration of neutropenia with > 7 days defining high risk for infection. 27 This high-risk state continues until hematological reconstitution, which, depending on the type of transplant, can fluctuate from 30 days in allogenic unrelated HSCT to 5 to 7 days in reduced intensity autologous transplants. 28, 29 In patients with acute GVHD, the period of neutropenia can be even longer. To make things worse, this period of profound neutropenia coincides with mucositis, technically abolishing the "front line" of the immune system (Fig. 2) .
The incidence of infectious pneumonias ranges between 15% and 25%. 30, 31 The pulmonary infectious processes that need to be differentiated during this period are bacterial, fungal, and viral including cytomegalovirus (CMV). Noninfectious etiologies such as engraftment syndrome (ES), FIGURE 1. Timeline and prophylaxis of pulmonary infections in HSCT recipients. HSV infections' very low incidence in the preengraftment period after acyclovir prophylaxis. *"Late-onset" infections once prophylaxis was stopped. **Usually antipseudomonal antibiotics and antimold prophylaxis are added in prolonged neutropenia. Breakthrough infections with pathogens not covered by the selected regimen. ***Center dependent and immunosuppression dependent. GNB indicates gram-negative bacilli; HSV, herpes simplex virus; TMP-SMX, trimethoprim-sulfamethoxazole; VZV, varicella zoster virus. FIGURE 2. Timeline and prophylaxis of pulmonary infections in solid organ transplant recipients. *"Late-onset" infections occurring now, once prophyaxis has been stopped. **According to the transplanted organ (see text). ***Prophylaxis is center and organ dependent. GNB indicates gram-negative bacilli; HSV, herpes simplex virus; TMP-SMX, trimethoprim-sulfamethoxazole. pulmonary edema, and acute GVHD all need to be considered in the differential diagnosis.
Bacterial infections after HSCT are breakthrough infections by pathogens that are not covered by the prophylactic antibiotic regimen. 32 In cohorts from the 1980s, the predominant group of bacteria was gram-negative rods (GNR), then, with the introduction of antibiotic prophylaxis and increase in the use of central lines, gram-positive cocci (GPC) became predominant. In the latest transplant era, predominance has shifted once again toward GNRs, now antibiotic resistant. 26 A highlight of recent multicenter surveys and cohort studies is that local incidence of different bacterial strains is highly variable. In the European Conference on Infections in Leukemia (ECIL) 4 survey, the ratio of GPC:GNR was 55%:45%, with a range of 30%:70% to 85%:15%, while rates of bacterial resistance were also highly variable between centers and geographical regions. 26 This heterogeneity highlights the importance of developing local epidemiological knowledge.
IMI are associated with a 1-year mortality as high as 75%. 33, 34 The port of entry for most molds is the respiratory tract after inhalation of spores. Of all fungal infectionsincluding fungemia-in HSCT, Aspergillus spp. was responsible for 49.5% of the episodes in the latest Prospective Antifungal Therapy Alliance (PATH alliance) update, while Candida spp. and other molds accounted for the remainder of the infections. 34 The incidence of fungal pneumonias is also higher than that of bacterial pneumonias in some series. Given their incidence and mortality, it is not surprising that the great majority of HSCT recipients, except for those in whom the duration of neutropenia is expected to be <14 days, will be on preemptive or mold prophylactic regimens. A common preemptive strategy consists of measuring galactomannan levels twice weekly and to initiate treatment if the levels increase beyond a preset threshold or if molds are detected in any diagnostic specimen. Posaconazole is a broad spectrum triazole active against Candida spp. as well as molds. 35 It has a low rate of breakthrough infections and was superior to fluconazole and itraconazole in randomized controlled trials (RCTs). 36 It is currently available in delayed release formulations and as an intravenous solution, which make it an ideal option for prophylaxis even in patients with severe mucositis. The other triazoles, voriconazole, itraconazole, and isuvaconazole are alternatives. For all of them to be effective, minimal therapeutic blood levels need to be achieved, and their measurement can also help guide diagnosis. The use of Amphotericin use as a prophylactic regimen is limited by its toxicity; however, some centers have used nebulized preparations as fungal prophylaxis. When mold infections occur while on prophylaxis, they are more frequently caused by resistant molds-for example, zygomycetes, Scedosporidium, and Aspergillus niger, if on voriconazole prophylaxis. 37 Overall, the use of prophylactic strategies has delayed the presentation of invasive fungal infections, with Aspergillus spp. becoming the predominant pathogen over Candida spp.
Historically, human CMV contributed to a significant proportion of deaths in HSCT recipients before the availability of effective antiviral treatment. 38 The development of ganciclovir in 1989 and of quantitative PCR and antigenemia resulted in a rapid decline in CMV disease and its most deadly complication, pneumonia, with current incidences in RCTs of <5%. 39 Both, CMV disease and valganciclovir or ganciclovir can cause neutropenia, and this represents a limiting factor for their use as prophylaxis before engraftment. Therefore, most centers opt for a preemptive strategy consisting of quantitative PCR or antigenemia monitoring with initiation of treatment once viremia surpasses a preset threshold. 39 In patients presenting with rising CMV-PCR titers and diffuse interstitial infiltrates, the diagnosis of CMV pneumonia should be strongly suspected. The incidence of CMV disease has decreased to such an extent that, in the latest RCT to test the efficacy of Letermovir, a new anti-CMV compound, the outcome was modified from CMV disease to the more prevalent diagnosis of clinically significant CMV viremia-viremia above the preemptive treatment threshold. 40 As this new antiviral does not cause neutropenia, its approval holds promise for its use prophylactically, particularly as the focus is now changing to preventing the long-term complications associated with CMV infection. Another clinically relevant characteristic of CMV infections is the frequent coinfection with bacterial and fungal pathogens; thus, an aggressive diagnostic workup is always warranted. 41 Community-acquired respiratory viruses including adenoviruses, influenza, parainfluenza, and respiratory syncytial virus can also cause disease early after transplantation 42 ; however, their incidence before engraftment is low, as most patients are still admitted to the hospital. Infections in HSCT recipients follow the same seasonal trends as in the community. HSCT recipients are more likely to suffer severe lower respiratory tract infections, late airflow obstruction, and polymicrobial infections with molds and bacteria. [43] [44] [45] For all fungal and viral infections, reduced intensity bone marrow transplants have a later onset of disease. 46 The use of reduced intensity regimens preserves part of the immune system of the recipient while allowing engraftment. The preserved recipient immune cells provide temporary protection against molds, bacteria. and viruses that wanes over time, and, after 100 days, the incidence of infections tracks that of myeloablative HSCT. 42 Finally, the differential diagnosis of pulmonary infections in HSCT should always include the possibility of noninfectious complications, the most common being chemotherapy side effects, radiation, 7 and the ES. 47 ES affects anywhere from 10% to 20% of HSCT recipients and coincides with improvements in the ANC. It is generally described in autologous SCT, but can happen in allogeneic transplantation, where the differentiation from acute GVHD is difficult. Patients develop skin rash, noncardiogenic pulmonary edema, and fever, and, as opposed to the infectious complications, it can respond to treatment with corticosteroids, 48 making the differentiation with infection essential.
Neutropenia in Solid Organ Malignancies
Unlike hematologic malignancies, most episodes of neutropenia in solid cancers are usually the result of bone marrow infiltration, chemotherapy, or multisite radiation therapy and are considered low risk for infectious complications. The neutropenia is usually short lived; therefore, the risk for infections caused by fungi such as Candida and Aspergillus spp. is considerably lower. Other factors to consider, which may increase risk, include the disruption of the mucocutaneous barrier and newer immunomodulating therapies (please see below). Comorbidities such as chronic obstructive pulmonary disease play a very relevant role in both increasing the predisposition to infection (including the risk for mold infections) and decreasing the likelihood of survival.
The location of the tumor can also promote infection. Lung malignancies, either primary or metastatic, can be associated with postobstructive pneumonias (20% to 30% of lung cancers), resulting in polymicrobial infections. These can evolve into lung abscesses and empyemas. Evolution over time and acuity of symptoms usually define the diagnosis.
Radiologic findings can identify airway obstruction, but the definitive diagnosis is made via bronchoscopy and, sometimes, transbronchial biopsies. There is a limited role for cultures, except for ruling out resistant microbes, such as methicillin-resistant Staphylococcus aureus (MRSA), extended spectrum betalacmase enterobacteriaceae, and Pseudomonas aeruginosa, as most of these infections will require prolonged broad antibiotics.
The dose and duration of corticosteroids also influences the risk of infection, especially in central nervous system malignancies without Pneumocystis jirovecii pneumonia (PJP) prophylaxis. PJP occurs in <2% of the solid tumor patients (non-HIV) when the prednisone dose or its equivalent is higher than 15 mg/d for > 4 weeks. Given the low incidence in these patients, the positive predictive value of staining methods usually used to diagnose PJP on induced sputum is low, and the chosen path usually involves highresolution CT imaging with 1,3-beta-glucan, combined with BAL plus PCR-based assays or PCP stains. High-dose prednisone use can also lead to pulmonary infections caused by Nocardia, Aspergillus spp., and endemic fungi.
Patients with head and neck cancers undergo surgeries and radiation therapies that leave them with an impaired swallowing mechanism, rendering them susceptible to aspiration pneumonias/ pneumonitis. In general, procalcitonin may be a useful tool in delineating infectious etiology, especially in pneumonias (see above). It can also help shorten the duration of antibiotics when it falls below the laboratory's threshold or by more than 80%. Radiation pneumonitis/radiation-induced lung injury and druginduced lung injury will also be included in the differential diagnosis of infectious etiologies. Symptoms such as dry cough, low-grade fever, shortness of breath, and pleuritic chest pain mimic those of typical pneumonia. CT imaging remains the test of choice in ruling out infectious etiologies. Sometimes, serum biomarkers such as SL-6 (expressed on bronchial cells and type II pneumocytes) and surfactant protein D may be utilized in detecting patients at high risk for radiation complications.
In general, as a lesser rate of long-term neutropenia is encountered in solid organ cancers, the most likely infectious complications remain those caused by the presence of malignancy (ie, postobstructive and aspiration pneumonia), along with common bacterial and viral infections (Streptococcus pneumoniae, Legionella, influenza), and infections caused by the prolonged use of corticosteroids (PJP, Nocardia, etc.).
NEUTROPENIA IN SOT
Similar to HSCT recipients, the early postoperative period after SOT is a phase of particular susceptibility to pulmonary complications including pulmonary infections. 49 Although neutropenia may occur, it is not a classical feature after SOT. While patients after SOT are not frankly neutropenic, treatments can result in dysfunctional neutrophils and predispose them to opportunistic infections seen in neutropenic patients.
The lung is the primary site of infectious complications in heart and/or lung organ transplant recipients. In liver, kidney, and small bowel recipients, the abdomen is most commonly affected by infection, followed by the lungs. By the time of transplantation, both the donor and recipient have been exposed to the hospital environment, and bacterial pneumonia is usually secondary to resistant GNRs and MRSA. The incidence has declined with the use of infection prophylaxis, and it now affects <5% of kidney, <10% of liver and cardiac, and <20% of lung transplants recipients. 50, 51 Despite the use of trimethoprim-sulfamethoxazole prophylaxis, there is still a risk of breakthrough infections with Nocardia spp. Most will still respond to therapeutic doses. In large-volume centers, Nocardia spp. libraries with antibiotic susceptibilities can be generated, and drug resistance presumed on the basis of subspecies' identification, usually carried out with 16s RNA sequencing. 52 IMI are more common in lung transplant and small bowel recipients. 34 Aspergillus spp. remains the most common etiology. However, with the use of prophylactic antifungals, the proportion of non-Aspergillus molds is increasing, similar to breakthrough bacterial infections. 37 Neutropenia is not a feature in SOT recipients who develop IMIs; similarly, the classic radiologic findings described in neutropenia are often missing. 8 Mold species exhibit different antifungal sensitivities, and a specific diagnosis should be obtained whenever possible to help guide treatment. Liver transplant recipients seem to have a disproportionate rate of infections with Mucorales spp., thought to be secondary to the iron overload of the cirrhotic liver.
In addition to pneumonia, lung transplant recipients are also susceptible to airway anastomotic infections. 53 Local ischemia and mechanical disruption of the mucosa with impaired clearance of secretions have been implicated. Epidemiologic reports of anastomotic infections are scarce, both bacterial and fungal pathogens being reported. In patients infected with Aspergillus spp., anywhere between 16% and 58% of the cases are confined to the airway. 8, 9 Many other molds, including, the Mucorales spp., Scedosporium, and endemic fungi such as Coccidioides spp. have been reported in monomicrobial and polymicrobial infections. Anastomotic dehiscence, obstruction, and metastatic distal infection should be evaluated with imaging and bronchoscopy. 8 The immunosuppressive regimen plays a determining role in the risk of infections and in the differential diagnosis. In SOT, the IS is generally divided into 3 periods, induction, maintenance, and, in some patients, rescue therapies for acute and chronic rejection. 54, 55 Induction and rescue regimens have higher intensity and include higher doses of standard maintenance drugs plus specialized induction agents and are, subsequently, associated with higher rates of infectious complications. Currently, interleukin-2 receptor antagonists (IL2R) are the most popular class of induction agents, while anti-CD52 antibody (Alentuzumab) and polyclonal antithymoglobulin (ATG) are used less frequently. 56 IL2R inhibitors are chimeric murine-human antibodies, and, compared with regimens without specialized induction agents (eg, high-dose steroids only), they are not associated with increased risk of bacterial, fungal, or viral infections. 57 The risk of CMV increases only in patients receiving IL2R inhibitors in combination with a second induction agent.
ATG is obtained from horses or rabbits immunized with thymocites or T-cell lines. These xeno proteins of ATG can be associated with fever, serum sickness, and pulmonary edema. 58 ATG increases the risk of CMV disease, but this risk can be overcome by the use of appropriate CMV-prophylaxis. 59 This agent also increases the risk of Ebstein Barr Virus-related posttransplant lymphoproliferative disease (PTLD). 60 Early PTLD will most frequently affect the transplanted organ, and, accordingly, pulmonary PTLD is more frequently seen in lung transplant recipients. ATG has been associated with falsely positive Histoplasma antigen tests.
Alemtuzumab results in pan T-cell depletion. It is associated with lower rates of early bacterial infections when compared with other induction regimens. 61 Infections with Mycobacterial spp. and Nocardia spp. have been reported mostly after the use of Alemtuzumab for the treatment of acute rejection and not during induction.
Belatacept belongs to a new class of induction agents targeting the costimulatory pathway of CTLA4 and CD28 that is necessary along with antigen recognition by T-cell receptors for activation of the immune response. It has been used mostly in renal transplantation, in an attempt to avoid the need for longterm maintenance with calcineurin inhibitors, which are associated with chronic renal failure. When comparing the 2 regimens -Betalacept without calcineurin inhibitor versus classic IS with a calcineurin inhibitor-containing regimen-Belatacept has higher rates of acute rejection, but, overall, it may increase renal graft survival. 62 Experience is still accumulating, and reports of infections are few, but late onset PJP, Aspergillus fumigatus, histoplasma, and Cryptococcus have been reported, and are consistent with a defect in cell-mediated immunity. Its mechanism of action is opposite to that of checkpoint inhibitors, and PTLD has also already been reported. The increased rates of rejection will probably prevent its use in thoracic transplant recipients.
Long-term IS most frequently consists of combinations of 3 drug classes, cell cycle inhibitors (mycophenolate, azathioprine), calcineurin inhibitors (tacrolimus and cyclosporine), and prednisone. Mammalian target of rapamycin inhibitors (sirolimus and everolimus) can also be used in chronic IS but are more frequently introduced once chronic rejection occurs. Mycophenolate mofetil increases the risk of bacterial, fungal, and viral infections in general, including CMV, but decreases the risk of PJP. Tacrolimus is reported to have antifungal properties and is synergistic in vitro when used along with azoles against resistant Candida spp. Overall, these findings are mostly of anecdotal importance, and the risk of a particular infection will depend on the "net level of IS" and the above-mentioned factors. In terms of pulmonary drug toxicities, mammalian target of rapamycin inhibitors are the most problematic class, generally causing diffuse ground glass opacities with lymphocytic alveolitis and anastomosis dehiscence, when initiated early after lung transplantation. 63 The infectious prophylactic regimens and their associated breakthrough infections are illustrated in Table 1 . 
HIV INFECTION
In the recent decades, important strides have been made in the HIV treatment arena with highly active antiretroviral therapy (HAART) being now widespread. The pulmonary system still remains the most affected organ in patients with HIV, with pulmonary infections and complications contributing significantly to the mortality and morbidity of patients with HIV. 64 However, the use of HAART has changed the epidemiology, clinical presentation, and even radiographic patterns of HIV-associated pulmonary conditions. Therefore, the differential diagnosis and clinical approach have changed, but chest thoracic imaging remains at the cornerstone of managing pulmonary conditions in patients with HIV/acquired immunodeficiency syndrome (AIDS).
With the widespread use of HAART, opportunistic infections have decreased in incidence, with new focus on noninfectious complications such as chronic obstructive pulmonary disease, lung cancer, and pulmonary hypertension. 65 While HAART has also lowered the incidence rates for Kaposi sarcoma of the lung and nonHodgkin lymphoma, the rates for other malignancies have not experienced the same beneficial trend. Patients living with HIV have an increased risk for developing lung cancer, 66 with the peak occurring during the first 5 years after diagnosis. Kaposi sarcoma, caused by HHV8 in MSM (men who have sex with men) is still encountered in burnedout AIDS and has some typical features on thoracic imaging. Of note, 20% of the patients may present with pulmonary findings only, lacking skin lesions. 67 With the initiation of HAART, a severe symptomatic immune reconstitution inflammatory syndrome (IRIS) can ensue. This often unmasks previous infections but can also solely cause sarcoid lung lesions on pulmonary imaging. The clinical presentation mimics infection, and the approach should be to rule out an opportunistic infection that would require immediate treatment while HAART is continued. Very rarely are steroids needed in patients with severe inflammatory symptomatology.
As previously mentioned, opportunistic pulmonary infections are less common in patients living with HIV while on HAART. For instance, even with CD4 counts between 100 and 200, patients whose viral load is suppressed by HAART may not require PJP prophylaxis. 68 Opportunistic infections still occur in severely immunocompromised hosts without access to HAART or who are travelling from abroad. Of note, many infections may coexist in a patient suffering from AIDS (eg, in 15% of the cases, P. jirovecii coexists with tuberculosis [TB]), hence, careful definitive diagnosis may be warranted. P. jirovecii remains the most common opportunistic infection, but with much lower rates in the era of HAART. Over 10 years between 1997 and 2007, the incidence has decreased to just over a tenth of its initial rate, falling from 29.9 to 3.9 per 1000 person years. 69 For unclear reasons, more cases are now being described in sub-Saharan Africa, an area where it was rarely described. 70 Clinically, patients present with fever, cough, and shortness of breath. The onset is gradual, over weeks, which is different from transplant patients. Thoracic imaging plays an important role in making the diagnosis, as many patients will be empirically treated on the basis of the clinical presentation and radiographic findings. Usually lactate dehydrogenase and 1,3-beta-D glucan are elevated, and the confirmatory diagnosis requires visualization of the cystic or trophic forms in bronchial secretions: expectorated or induced sputum, oral washes, endotracheal sputum, or BAL. In the past, multiple staining methods (eg, GrocottGomori methenamine silver, Giemsa, Wright, Diff-Quick, calcofluor white, etc.) have been used, usually with sensitivities ranging between 50% and 80% and high specificities > 99%. 71 These histologic staining techniques are being replaced by immunofluorescense antibody staining along with PCR testing. Even though the specificity is lower compared with calcofluor, immunoflourescence staining has significantly better sensitivity, including on sputum samples. 72 PCR testing can be performed but does not differentiate between colonization and active infection. Its use on expectorated or induced sputum may provide a more cost-effective approach in countries with a high prevalence. 73 When a host at risk (late stages of AIDS, not on HAART) presents with the typical gradual onset symptoms and a compatible thoracic imaging, a presumptive diagnosis of Pneumocystis pneumonia is made. Treatment is usually initiated at this stage while waiting for the confirmatory diagnosis.
Across the globe, the second most common opportunistic pulmonary infection in patients with HIV remains TB. 74 In the United States, TB presents as a new infection rather than reactivation, in patients with additional risk factors such as homelessness, incarceration, and intravenous drug use. Use of HAART has modified not only the clinical presentation of TB but it has also decreased its incidence. These new strategies initiate HAART early on, before the decline of immune function. When HAART was initiated at CD4 > 500 cells/μL, the incidence of TB had an adjusted hazard ratio of 0.27 (95% confidence interval, 0.12-0.62), compared with initiation at CD4 counts <500 cells/μL. 75 Ongoing HIV viral replication represents an important risk factor for TB, irrespective of the CD4 count, emphasizing again the role for sustained HAART. 76 In patients with high CD4 counts above 350 cells/μL, the presentation of TB mimics the usual subacute symptoms of nonimmunocopromised hosts: cough sometimes with hemoptysis, fevers, chills, night sweats, and weight loss. The presence of subacute systemic symptoms (eg, night sweats, weight loss) differentiates TB from most other infections more commonly characterized by localized symptoms such as cough, pleuritic chest pain, and dyspnea. The lower the CD4 count, the higher the chances of disseminated TB with a more fulminant course.
As with other pulmonary infections, radiographic imaging represents the first step in the diagnostic work-up, and chest x ray tends to correlate with the CD4 count. When the CD4 count is > 200 cells/μL, a typical postprimary infection appearance is common. At lower CD4 counts, chest x ray findings vary from normal to miliary pattern. The use of HAART has changed previously described patterns, 77 and, as such, postprimary radiographic findings have increased in incidence, now making up close to 50% of the TB cases.
When TB is suspected on the basis of epidemiologic clues and clinical presentation, the patient should be placed on airborne isolation while active disease is being ruled out. Skin testing and interferon gamma release assays do not differentiate between latent and active TB, and, moreover, false-negative results do occur in the setting of immunocompromise. 78 Therefore, the diagnosis relies on demonstrating Mycobacterium tuberculosis in sputum samples. The initial step is to obtain 3 induced sputum samples, which is the safer approach in terms of infection control and is also more cost-effective compared with bronchoscopy, even in patients who do not produce sputum spontaneously or are smear negative. 79 In recent years, nucleic acid amplication tests have been used for a rapid diagnosis of TB. To date, 2 tests (E-MTD, Gen-Probe, San Diego, CA and Amplicor, Roche Diagnostics) are approved for use in the United States. While both tests have a sensitivity > 95% when used on smear-positive samples, E-MTD has better sensitivity of 70% to 90% versus 60% to 70% on smearnegative specimens. 80 While IRIS can unmask TB, it can also unmask infections caused by nontuberculous mycobacteria. In the late stages of HIV infection, mycobacterium avium intracelulare usually manifests as disseminated disease affecting the bone marrow, liver, spleen, and lymph nodes without pulmonary involvement. Pulmonary focal involvement is occasionally seen with Mycobacterium kansasii and Mycobacterium xenopi.
IRIS-unmasked pulmonary infections occur soon after initiation of HAART, but infection with communityacquired organisms can occur throughout the course of HIV infection. Even though the incidence of pneumococcal pneumonia has decreased due to access to HAART, its relative contribution increased when compared with other pulmonary infections. 81 Similar to its success in diminishing the incidence of TB, initiation of HAART upon entry into care at CD4 counts > 500 cell/μL lowers the patient's risk of bacterial infections > 50% compared with patients started on HAART at CD4 <350 cells/μL. 82 Pneumonia was the most common diagnosis. Nevertheless, pneumococcal pneumonia and acute bronchitis remain common diagnoses even in HIV patients with high CD4 counts, especially in smokers and malnourished patients with unsuppressed viral loads. Pneumococcal vaccines are now universally recommended, in patients with HIV, although disease-specific data are not very prevalent. 83 The robustness of the immune response depends on the CD4 count as well as initiation of stable HAART. A better and longer lasting immune response is obtained by using a prime-boost effect of PCV7 followed by PPSV23. 83 Other etiologies for bacterial pneumonias are Haemophilus influenzae and Legionella pneumophila (40 times more commnon than in the general population). When an aggressive diagnostic pursuit is utilized, atypicals are isolated in 10% of the cases, 84 along with S. aureus and other rare bacteria such as Nocardia spp. and Rhodococcus spp. Nosocomial pathogens such as MRSA, Pseudomonas spp. dominate the microbiology of hospital-acquired pneumonia, especially in patients with neutropenia caused by advanced AIDS.
The clinical symptoms are very acute with cough (sometimes productive of sputum), fevers, chills, and pleuritic chest pain differentiating bacterial pneumonias from the more subacute presentation of PJ and TB. Diagnostic workup relies on microbiological identification via sputum cultures, urinary antigens, or cultures of the pleural fluid. Regardless of the HIV status, pneumococcal urinary antigen offers a reliable diagnostic tool. In 60% of the cases of pneumococcal pneumonia, blood cultures also return positive for S. pneumoniae. HIV patients have a higher risk for invasive pneumococcal disease due to higher rates of colonization, lower protection from the vaccines, and, also, humoral deficiency despite polyclonal hypergammaglobulinemia. In contrast, virologically suppressed patients with CD4 counts > 350 cells/μL have similar outcomes to non-HIV patients. 85 Common pulmonary infections in the general population, such as acute bronchitis and viral respiratory infections, remain common in the HIV population as well. Influenza may have a more severe clinical presentation. CMV contributes to significant morbidity in HIV patients, but its role in pneumonitis remains unclear. 86 Undoubtedly, immunocompromised hosts, including HIV patients, reactivate CMV in brochoalveolar secretions. It is common for CMV to have a similar clinical presentation as PJ and to be isolated along with it, but, unless a cytopathic effect is demonstrated, treatment is not necessary. CMV pneumonitis occurs very rarely in patients with CD4 counts <50 cells/μL, and old studies have shown no additional benefit when CMV that is treated along with PJ.
Depending on the geographical area, reactivation of endemic mycoses (Histoplasma capsulatum, Cryptococcus spp., and Coccidioides immitis) contribute significantly to pulmonary infections in HIV patients. At high CD4 counts, symptoms may be localized to the lung with chest pain, shortness of breath, and cough, while more immunocomcpromised patients may present with disseminated disease and septic picture. While Histoplasma affects the reticulo endothelial system, Cryptococcus neoformans is a frequent cause for meningitis and skin lesions. In localized pulmonary disease or in patients with high CD4 counts, the antigens (H. capsulatum and C. neoformans) may remain negative. Histoplasma serologies may be useful in disseminated disease. C. immitis follows a pattern similar to Histoplasma, with findings confined to the lung with high CD4 counts and dissemination to the central nervous system, liver, and skin at low CD4 counts. Sputum or tissue cultures make the diagnosis for fungal etiologies along with serologies and antigens.
Uncommon fungal etiologies responsible for pulmonary complications in HIV include Penicillium marneffei, Aspergillus spp. Parasitic infections caused by Toxoplasma gondii, Strongyloides stercoralis, Cryptosporidium, and Microsporidium may also be encountered.
INFECTIONS SEEN WITH IMMUNE SUPPRESSIVE TREATMENT OF NON-NEOPLASTIC DISEASE
Connective tissue disorders comprise another group of disorders characterized by immune dysregulation at multiple levels. Immune defects include damage to anatomic barriers caused by pulmonary pathology associated with the underlying disease and by medication adverse reactions and infectious complications. We will only briefly focus on tumor necrosis factor alpha (TNF) inhibitors in the next paragraphs.
Biologics such as anti-TNF alpha drugs, have been approved for a significant number of autoimmune diseases, with infections being a common adverse event. Because of the pathophysiology of the TNF alpha pathway in granuloma formation, these medications carry a high risk of granulomatous infections (mycobacterial infections and fungal). This risk is higher with monoclonal antibodies (eg, infliximab) than with other TNF alpha inhibitors. While TB is usually secondary to reactivation, fungal infections (histoplasmosis, coccidioidomycosis, and blastomycosis) are usually acutely acquired new infections. Therefore, screening for TB is mandatory, but it remains unclear whether serologic screening for fungal diseases adds to the risk profile. The risk of infection is increased by multidrug therapy, usually with corticosteroids and methotrexate, and by the baseline disease and its complications (eg, rheumatoid arthritis (RA) may intrinsically increase the risk for TB).
Mainly a reactivation disease, TB symptoms usually develop earlier than with newly acquired infection (eg, 3 mo for infliximab). Clinical presentation is often similar to TB in immunocompetent hosts, but > 50% of patients may present with disseminated disease. A meta-analysis that included rheumatologic diseases and also inflammatory bowel disease found the highest incidence for RA patients treated with infliximab.
Clinical workup is similar to patients not treated with biologics: chest imaging, followed by isolation of M. tuberculosis including susceptibility panel and antibiotic susceptibility testing.
Legionellosis is caused by Legionella pneumophila, an intracellular gram-negative coccobacillus. Its symptomatology is similar to community-acquired pneumonia, and patients can even present with acute hypoxemic respiratory failure requiring mechanical intubation. Legionella infections occur most commonly at 1 to 80 months after initiating treatment with biologics. Usually the diagnosis is made with rapid diagnostics (urinary antigen or PCR), and chest imaging may help differentiate it from other causes of pneumonia. After 80 reported cases, FDA added the increased risk of legionellosis to the drug labels of all TNF alpha blockers.
The most prevalent endemic fungal infection is histoplasmosis, but coccidioidomycosis and blastomycosis can also occur, especially in patients treated with infliximab. Histoplasmosis is endemic across the Midwestern and Central American states but also in central and South America, Africa, and Asia. Presenting symptoms are nonspecific: fever, malaise, cough, and weight loss, which may delay the diagnosis and treatment. Patients may present with disseminated infection in septic shock. Chest imaging may be very valuable in raising the suspicion for histoplasmosis. In the largest retrospective study that included 98 patients with histoplasmosis, the urinary antigen level correlated with severity and dissemination of disease. 86, 87 TNF alpha blockers were restarted, after 12 months of antifungal therapy, with 2/3 recurrences occurring in this group.
CONCLUSIONS
The relationship between immunosuppression and pulmonary infections is complex, involving both the innate and adaptive immune systems. This relationship is also nuanced, as demonstrated by the differences in infectious complications in patients with neutropenia related to HSCT and neutropenia related to therapy for solid organ tumors. These complexities are now navigated both with thoracic imaging and with a variety of novel diagnostic agents, including galactomannan antigen, procalcitonin, and many less widely available laboratory tests.
Recent advances in therapy for the underlying disease and for infection prophylaxis also need to be factored into the management of respiratory infections. These changes may diminish the clinical importance of some pathogens, but increase that of others. The advent of ganciclovir and valganciclovir for CMV prophylaxis and of PCR for CMV viremia surveillance has dramatically decreased the incidence of this infection in transplant recipients. The availability of HAART has depressed the relative prevalence of PJP, but increased that of pneumococcal pneumonia among patients with HIV infection. These kinds of changes in our understanding of immune suppression and in our clinical response to it are likely to continue to progress in the future.
